Trillium Therapeutics (TRIL) Stock Price, News & Analysis

Company Overview

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: $18.44 to $18.44
• 50-Day Range: $17.50 to $18.44
• 52-Week Range: $5.80 to $20.96
• Volume: 8 shs
• Average Volume: 1.87 million shs
• Market Capitalization: $1.94 billion
• P/E Ratio: 29.74
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TRIL Stock Analysis - Frequently Asked Questions

How were Trillium Therapeutics' earnings last quarter?

Trillium Therapeutics Inc. (NASDAQ:TRIL) posted its earnings results on Thursday, November, 18th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01.

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Trillium Therapeutics investors own include NVIDIA (NVDA), CannaPharmaRX (CPMD), FuelCell Energy (FCEL), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/18/2021
• Today: 2/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TRIL
• CUSIP: N/A
• CIK: 1616212
• Web: www.trilliumtherapeutics.com
• Phone: (416) 595-0627
• Fax: N/A
• Employees: 33
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.62
• Trailing P/E Ratio: 29.74
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-59,350,000.00
• Net Margins: N/A
• Pretax Margin: -113,720.92%
• Return on Equity: -23.31%
• Return on Assets: -18.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.82
• Quick Ratio: 19.82

Sales & Book Value

• Annual Sales: $150,000.00
• Price / Sales: 12,907.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.56 per share
• Price / Book: 7.20

Miscellaneous

• Outstanding Shares: 104,995,000
• Free Float: 95,440,000
• Market Cap: $1.94 billion
• Optionable: Optionable
• Beta: 2.08